9th Annual Biomarkers Congress

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Intravesical chemotherapy and immunotherapy for non-muscle invasive bladder cancer 30th Anniversary meeting Jackson Hole Seminar, Jackson Hole, Wyoming January, 2010
2. Things I ve learned from my friends Issues & Controversies in Prostate Cancer, Las Vegas, Nevada January, 2010
3. Panelist Session Locally advanced bladder cancer: case discussion 3rd World Congress on Controversies in Urology (CURy) January, 2010
4. GSK Avodart National Advisory Board Meeting, Toronto. GSK Avodart National Advisory Board Meeting, Toronto. January, 2010
5. How will this affect Decision making or outcome? 10th Annual meeting of the Society of Urologic Oncology, Bethesda, MD December, 2009
6. GSK Avodart National Advisory Board Meeting, Quebec GSK Avodart National Advisory Board Meeting, Quebec December, 2009
7. Perspectives dans le traitement du cancer du rein et de la prostate au stade avance. Association quebecoise d urologie (AUQ) et Association francaise d urologie (AFU), Paris November, 2009
8. Challenging cases in bladder cancer management 30th Congress of the Societe internationale d urologie, Shanghai November, 2009
9. Bladder cancer sesin: BCG failure: What to do next? 30th Congress of the Social internationale d urologie, Shanghai November, 2009
10. Management of high risk prostate cáncer: RP+XRT+ADT vs XRT/ADT World Urologic Oncology Federation, Shanghai, 2009 October, 2009
11. Mise a jour fondee sur des preuves sur les analogues de la LHRH dans le cancer de la prostate Conseil consultatif regional du Quebec en uro-oncologie, Montreal October, 2009
12. Opening ceremony Key-note lecture - Quality of Surgery as a critical determinant of outcome in Urological Cancers. Urology Acapulco meeting, Mexico July, 2009
13. MP38 Bladder cancer Detection and screening Canadian Urological Association annual meeting, Toronto, Canada June, 2009
14. Bladder Cancer 2009: Challenges and opportunities Robson Research Day Visiting Professor, Division of Urology, University of Toronto April, 2009
15. MP38 Bladder cancer Detection and screening American Urological Association annual meeting, Chicago, USA April, 2009
16. PSA and beyond: tumor markers for prostate cancer; Urology Update 2009, Baylor Health Care System, Dallas, Texas March, 2009
17. Non-muscle invasive bladder tumors 2nd World Congress on Controversies in Urology (CURy), Lisbon, Portugal January, 2009
18. Peter Ekman, Faculty: Yves Fradet, Gerald Andriole, Stefan Carlsson, Marcus Graefen SIU World Uro-Oncology Update, Santiago, Chile November, 2008
19. Active surveillance in prostate cancer Quebec Urological Association meeting, Quebec November, 2008
20. Current issues and controversies in the management of prostate cancer: role of PCA3, surgery, and hormonotherapy Urology Grand Round Speaker University of California San Francisco October, 2008
21. Urological Research Society meeting, Amsterdam, The Netherlands Urological Research Society meeting, Amsterdam, The Netherlands September, 2008
22. Optimal management of high risk prostate cancer: role of surgery, radiotherapy and hormone therapy Annual meeting of the Korean Urological  Oncology Society, Seoul August, 2008
23. Prevention and detection of bladder cancer Bladder Cancer Research Network Think Tank 2008 August, 2008
24. 2020 My vision Educational meeting for French Urologists on the management of bladder cancer, Paris, France June, 2008
25. PCA3 based molecular diagnostic prostate cancer Prostate Cancer Research Foundation Forum 2008, Toronto June, 2008
26. Moderator Educational forum on bladder cancer Multidisciplinary treatment approach to invasive bladder cancer Canadian Urological Association meeting, Edmonton, Alberta June, 2008
27. Prostate disease prevention and risk reduction: an interactive forum. Program Chair GSK Symposium Satellite June, 2008
28. Critical Discussion The evolution of markers for urologic cancer Presenter: Urine based PCA3 assays American Urological Association Annual meeting, Orlando, USA May, 2008
29. Dialogues in prostate cancer prevention GlaxoSmithKline Prostate Cancer Advisory Board, Toronto April, 2008
30. Cases of advanced bladder cancer Urological Society of Australia & New Zealand, HongKong January, 2008
31. Role of lymph node dissection in prostate cancer Issues & Controversies in Prostate Care (ICPC) 2008, Cancun January, 2008
32. 2007 Northwest Urological Society meeting, Vancouver 2007 Northwest Urological Society meeting, Vancouver December, 2007
33. Urologic Oncology 8th Annual meeting of the Society of Urologic Oncology November, 2007
34. Role de la prostatectomie radicale dans les cancers a haut risque Universite de Montreal Visiting professor (GlaxoSmithKline sponsorship) October, 2007
35. Chemoprevention of prostate cancer: Are we there yet? University of Ottawa Visiting professor (GlaxoSmithKline sponsorship) October, 2007
36. Impact of cost of new therapies in a closed health-care budget The experience in the Province of Quebec C2 Retreat (CURC & CUOG Retreat )New Technologies & New Therapies, Vancouver October, 2007
37. Prostate Cancer Conference 2007 Prostate Cancer Conference 2007 September, 2007
38. Oncology Federation (WUOF) in conjunction with the SIU, Paris, France - Member of the Steering committee 3rd World Urologic Oncology Conference September, 2007
39. What is the Future of Urologic Oncology Centennial Congress of the Societe internationale d urologie, Paris, France September, 2007
40. Invited CUASF lecture - Bladder cancer screening and innovative therapies: a quest of 20 years ready for prime time? Canadian Urological Association annual meeting, Quebec June, 2007
41. Moderator Poster session #MP41 on Kidney cancer: Evaluation & Treatment (VI) Annual meeting of the American Urological Association, Anaheim, California May, 2007
42. Radical prostatectomy is the best initial treatment for high risk prostate cancer; 27th Athenian Days of Urology, Athens, Greece April, 2007
43. Moderator poster session European Association of Urology Berlin March, 2007
44. GlaxoSmithKline Dialogues in prostate cancer prevention Chairman of the meeting January, 2007
45. International Bladder cancer Research Workshop, Houston, Texas International Bladder cancer Research Workshop, Houston, Texas January, 2007
46. Optimal initial treatment for high-risk prostate cancer Issues and Controversies in Prostate Care, Cancun, Mexico Meeting, January, 2007
47. Molecular approaches to therapy New strategies Prostate Cancer Research Retreat, Orangeville, Ontario January, 2007
48. Surgical, Pharmacological and technological Advances in Adult and Pediatric Urology New York University Post-graduate Medical School CME program December, 2006
49. Representant de lAmerican Urological Association Association francaise d Urologie, Paris December, 2006
50. Prostate Cancer Surgery 28th Congress of the Societe internationale d urologie, Capetown, South Africa November, 2006
51. Survol pharmacologique et du mode d action des inhibiteurs de la 5-alpha-reductase Conseil consultatif regional du Quebec sur Avodart, Montreal November, 2006
52. 2nd GU Oncology Conference 28th Congress of the Societe internationale d urologie, Capetown, South Africa November, 2006
53. Seance #3 Communications orales Tumeurs superficielles de vessie 100e Congres de l Association francaise d urologie, Paris November, 2006
54. Challenges and opportunities in the management of bladder cancer London Health Sciences Centre Uro-Oncology Fall Retreat, Niagara-on-the-Lake, Ontario September, 2006
55. Searching for novel therapeutics and targets: insights from clinical trials Bladder Cancer Conference: Outside the Box #1: Bladder Cancer Think Tank, Aspen, Colorado August, 2006
56. The management of non-muscle invasive bladder cancer: an update Visiting professorship, St Boniface General Hospital, Winnipeg June, 2006
57. Take home message presenter Bladder Cancer Annual meeting of the American Urological Association, Atlanta, Georgia May, 2006
58. Avodart National Advisory Board, Toronto Avodart National Advisory Board, Toronto April, 2006
59. EAU Paris EAU Paris April, 2006
60. Genitourinary Surgeons, Boca Annual meeting of the American Association April, 2006
61. Prostate Cancer Research Foundation Scientific & Medical Advisory Committee Grant review meeting, Toronto March, 2006
62. Welcome/Introductions/Session Objectives/Roles and Responsibilities/Ajourn Dialogues in Prostate Cancer Prevention, GlaxoSmithKline Board Meeting, March, 2006
63. Tailoring Follow-Up & Prevention of Recurrence for Patients with Superficial Bladder Cancer Current Problems in Urology Banff January, 2006
64. Bladder Cancer Kidney Cancer Prostate Cancer Sessions 16th Annual International Challenging Cases in Urology, Miami, Florida January, 2006
65. Advancing Prostate Cancer session. Issues & Controversies in Prostate Cancer Phoenix, Arizona January, 2006
66. Risk stratification and natural history Surgical Wait Times Initiative Fall meeting, Ontario December, 2005
67. Therapy of superficial bladder cancer 6th Annual meeting of the Society of Urologic Oncology, Bethesda, Maryland December, 2005
68. PCA3, a new molecular urine test for prostate cancer diagnosis. Annual meeting of the Urologic Research Society, Boston, Massachusetts November, 2005
69. Reconstruction vesicale : Reflexion sur le choix des 30ieme Congress annuel de l Association des Urologues du Quebec, Quebec Conferencier. November, 2005
70. Depistage et diagnostic Colloque sur le cancer de la prostate, Montreal November, 2005
71. Diagnostic and therapeutic challenges of prostate cancer management and new opportunities Dalhousie University, Residents Research Day, Halifax November, 2005
72. Plenary Session I: Prostate cancer 57th Joint Annual meeting of the Northeastern Section of the American Urological Association, Bermudas November, 2005
73. Diagnosis and detection of prostate cancer Iowa Urologic Post-graduate Conference, Iowa, USA September, 2005
74. Road map to the future. Roswell Park Cancer Institute, Buffalo, New York July, 2005
75. Everyday cases in the context of PCPT and MTOPS Canadian Urological Association Satellite Symposium, Ottawa June, 2005
76. Poster session on Basic Science 60th Annual meeting of the Canadian Urological Association, Ottawa June, 2005
77. Moderator: Podium session on Prostate cancer: Advanced II American Urological Association annual meeting, San Antonio, Texas May, 2005
78. Evolution of multimodal approach to prostate cancer: Practical application Issues & Controversies in Prostate Cancer 2005 Jamaica March, 2005
79. Management of superficial bladder cancer. 25th Annual Anniversary Jackson Hole Conference, USA January, 2005
80. Flomax National Advisory Board meeting, Toronto Flomax National Advisory Board meeting, Toronto January, 2005
81. Faculty member guest speaker: New markers 2005 ASCO Prostate Cancer Symposium, Orlando, Florida January, 2005
82. Available markers: ImmunoCyt, multiparameter FISH, BCLA-4 Fifth annual Urologic Oncology meeting of the Society of Urologic Oncology, Bethesda, Maryland November, 2004
83. The technique of open retropubic radical prostatectomy Mexican Society of Urology, Merida November, 2004
84. Invited SIU lecturer: Current concepts of chemotherapy in bladder cancer 56th Congress of the German Association of Urology, Wiesbaden, Germany September, 2004
85. What does it all mean? Clinical implications of two landmark trials. Canadian Urological Association Satellite symposium June, 2004
86. Radical surgery vs bladder preservation using multimodality treatment in the management of invasive bladder cancer Annual conference on Current Problems in Urology 2nd Edition, Quebec June, 2004
87. Optimal timing of early hormone therapy Society of Urologic Oncology annual meeting, San Francisco, CA May, 2004
88. Case management of bladder cancer American Urological Association meeting, San Francisco, CA May, 2004
89. US-Franco meeting, San Francisco, CA US-Franco meeting, San Francisco, CA May, 2004
90. Bladder & Prostate Cancer panels 14th International Challenging Cases in Urology, Miami, Florida January, 2004
91. Molecular genetics of bladder cancer progression Bladder cancer Spanish Network meeting, Barcelona, Spain November, 2003
92. Urology Update University of Toronto November, 2003
93. Funding leveraging strategy CANVAC Research Management Committee meeting, Toronto November, 2003
94. AstraZeneca Casodex 7054IL/0044 Canadian investigators meeting, Montreal September, 2003
95. Debate: Laparoscopic vs open procedures (Drs Andriole and Guillonneau) 55th Annual meeting of the Northeastern section of the American Urological Association September, 2003
96. Bladder cancer Association des urologues du Quebec Colloque Post AUA 2003, Chateau Frontenac June, 2003
97. Canadian Advisory Board . ACMI International , Boston, USA May, 2003
98. Role of radical prostatectomy in high risk prostate cancer Issues & Controversies in Prostate Cancer, Whistler, B.C. March, 2003
99. Superficial bladder tumors 2003 Prairie Urological Association meeting, Edmonton, Alberta January, 2003
100. Molecular urine assay prostate cancer detection 3rd Annual meeting of the Society of Urologic Oncology, Bethesda, MD December, 2002
101. Diagnosis and monitoring of superficial transitional cell carcinoma Strong Memorial Hospital, Rochester, New York November, 2002
102. 96ieme Congres de l Association Franaise d Urologie, Paris, France 96ieme Congres de l Association Francaise d Urologie, Paris, France November, 2002
103. Cancer de la prostate localement avance : Options therapeutiques et controverses 27ieme Congres de l Association des Urologues du Quebec, Montreal November, 2002
104. Assessment: lessons from the p53 standardization trial Chairmen International Bladder Cancer Network/ESUR Congress, Trento, Italy October, 2002
105. Organ confined and locally advanced prostate cancer live surgeries 5th International Symposium on Uro-oncology, Marburg, Germany October, 2002
106. Cancer de la prostate: depistage, chirurgie et traitements Colloque sur la mise a jour et Controverses en uro-oncologie : Groupe d etude en Oncologie du Quebec, Manoir du Lac Delage, Quebec October, 2002
107. 26th Congress of the Societe Internationale d Urologie, Stockholm, Sweden Chairman, Scientific Committee September, 2002
108. Whats new in superficial bladder cancer, diagnosis, staging and management. Invited professor Mexican Society of Uro-Oncology, Acapulco, Mexico July, 2002
109. Recent advances in understanding and managing superficial bladder cancer Visiting professor University of North Carolina, Chapel Hill June, 2002
110. Role of surgery in high-risk prostate cancer - Role of adjuvant hormone therapy 2002 Uro-Oncology Congress Montego Bay, Jamaica January, 2002
111. Panellist for the session: Le depistage precoce du cancer de la prostate: les preuves de son avantage sont-elles rÆ’eunies? XXVIth Annual meeting of the Quebec Urological Association, Montreal November, 2001
112. New Ideas, Approaches, and Techniques Continuing Education Urology Update 2001 November, 2001
113. 1st presentation: Treatment of Ta-low grade bladder TCC Canadian Senior Resident Urologic Oncology Course Montreal October, 2001
114. Why is the clinical application of the newer prognostic markers still not possible? International Consultation on the Diagnosis of Non Invasive Urothelial Neoplasms, Ancona, Italy Chairman on the Committee: Detection methods other than morphology, molecular pathology, and cytometry May, 2001
115. Poster session on Advances in the diagnosis of bladder cancer XVIth Congress of the European Association of Urology and AstraZeneca Canadian Medical Ambassadors Program, Geneva, Switzerland April, 2001
116. How to improve your prostatectomy: pearls from my practice Issues & Controversies in Prostate Cancer Whistler March, 2001
117. Superficial bladder cancer: Molecular markers for detecting recurrences. 2001 Congress on Uro-oncology: A Canada-Mexico Alliance, Ixtapa, Mexique January, 2001
118. Uro-oncology in action: Exploring the options for a better tomorrow Chairman of the AstraZeneca Uro-oncology Advisory Board meeting, Las Vegas January, 2001
119. Diagnosis, risk factors and management of T1G3 bladder cancer 11th Annual Challenging Cases in Urology, Orlando, Florida January, 2001
120. AstraZeneca Speakers Update meeting and Early Prostate Cancer (EPC) investigator meeting, Orlando, Florida Early Prostate Cancer (EPC) January, 2001
121. Molecular Diagnostic and Prognostic Factors & Presentation to the residents in Urology of MCP-Hahnemann University Fifth Annual Prostate Symposium, Philadelphia, PA December, 2000
122. Prostate Cancer: PROstart-First Global Workshop on Prostate Cancer: New principles in patient care Barcelona, Spain December, 2000
123. Tumeurs de vessie: Marqueurs, facteurs pronostiques 94th Congress Franais d Urologie (AFU) November, 2000
124. Laparoscopie vs prostatectomie radicale ouverte: perspective canadienne Symposium Satellite: Le cancer de la prostate au Canada du diagnostic au traitement, Social internationale da urologie, section canadienne, Singapore November, 2000
125. Controversies in uro-oncology, the enigma of chronic prostatitis advances in the management of prostatic diseases. Autumn meeting of the European Organization for Research and Treatment of Cancer November, 2000
126. The role of cystectomy, lymphadenectomy 16th Turkish Urological Congress, Izmir/Turkey October, 2000
127. Markers of progression in urological cancer 15th European Society for Urological Research Congress, Istanbul/Turkey October, 2000
128. Use of markers for the detection and management of patients with bladder cancer 25TH Congress of the Social Internatinale d Urologie, Singapore October, 2000
129. Comment prevenir le cancer de la prostate ? Swiss Cancer League & Swiss Urological Society -Prostate Cancer Symposium Interlakin, Swiss September, 2000
130. Risk factors and indication for intravesical therapy McGill University Educational program September, 2000
131. AstraZeneca Casodex Monotherapy Clinical Review Meeting, New York AstraZeneca Casodex Monotherapy Clinical Review Meeting, New York July, 2000
132. Hormonotherapie neoadjuvante ou adjuvante: y a-t-il un approche logique? Abbott Laboratories Advisory Board meeting, Nassau, Bahamas May, 2000
133. Session on Bladder Cancer: Problems and solutions 95th Annual meeting of the American Urological Association, Atlanta, Georgia May, 2000
134. Chairman Oral session entitled: Bladder tumors: enhancing the diagnosis XVth Congress of the European Association of Urology, Brussels, Belgium April, 2000
135. The influence of diet on the progression of prostate cancer XVth Congress of the European Association of Urology, Brussels, Belgium April, 2000
136. Role of BCG therapy in patients with stage T1G3 bladder cancer McGill Urology Continuing Medical Education meeting/Brazilian Urological Congress in Rio de Janeiro, Brazil November, 1999
137. Nouvelles perspectives dans la prise en charge des tumeurs superficielles de vessie et des cancers de la prostate a haut risque Service d Urologie, Centre hospitalier unieversitaire de Rouen, France November, 1999
138. Tumor markers and their role in management of bladder cancer 3rd International Symposium on Uro-Oncology November, 1999
139. Superficial bladder tumors XXVII Brazilian Congress of Urology November, 1999
140. Molecular markers for bladder cancer International Baltic Uro-Oncologic Symposium on Bladder Cancer and Urinary Diversion, Kiel, Germany June, 1999
141. Round table discussions: Early vs Delayed Hormonal Therapy Canadian Perspective on Current Issues in Prostate Cancer Zeneca s EAU 1999, Stockholm, Sweden April, 1999
142. Guest speaker: Le suivi clinique en fonction des facteurs de risques de reÆ’ecidive des tumeurs non-envahissantes de la vessie Association des urologues du Quebec- Scientific annual meeting April, 1999
143. A Growing Role in the Treatment of Early Prostate Cancer Zeneca Pharmaceutical Symposium Stockholm, Sweden April, 1999
144. Les marqueurs en urologie 20th Seminaire d urologie de I Ouest, Angers, France March, 1999
145. Managing superficial bladder cancer University of Vancouver, British Columbia January, 1999
146. Is there a role for aggressive treatment of high risk localized prostate cancer? University of Hannover, Germany November, 1998
147. International Symposium Strategies for the Chemoprevention of Prostate Cancer 20th Anniversary of the Department of Urology, University Libre de Bruxelles October, 1998
148. Influence of dietary factors on the evolution of prostate cancer. International Symposium Strategies for the Chemoprevention of Prostate Cancer, Brussels, Belgium October, 1998
149. The role of diagnostic and tumor markers in the 21st century Tokyo Urological Research Forum, Tokyo, Japan September, 1998
150. Collin s Day (annual research day) University of Ottawa, Department of Surgery May, 1998
151. Role des nouveaux tests diagnostiques et pronostiques dans le traitement du cancer de la vessie. Universite de Sherbrooke April, 1998
152. Progress in molecular markers of bladder cancer McGill Urology Research Labs. Seminar Series, Montreal April, 1998
153. Advances in Uro-oncology 98 The role for new diagnostic and prognostic tests in the management of superficial bladder cancer. March, 1998
154. Detection of bladder cancer by a monoclonal antibody test : ImmunoCyt Sarasota Bladder Cancer Meeting, Sarasota, Florida January, 1998
155. Bladder cancer : non-invisaive diagnostics and follow-up. Department of Urology, University of Rotterdam, The Netherlands January, 1998
156. Traitement du cancer de la prostate a haut risque et etat des connaissances sur le role de l hormonotherapie Symposium de l Association franaise d Urologie, PARIS November, 1997
157. Assessment with DNA, genetic markers, and molecular biology: What factors do govern the invasive and/or metastatic potential ? 5th International Bladder Consensus Conference November, 1997
158. Phenotypic characterization of bladder cancer. 6th Symposium of the Heinrich Warner Foundation Hamburg October, 1997
159. Early detection of prostate cancer International Congress on Prostate Cancer, Beyrouth, Lebanon October, 1997
160. New developments in hormonotherapy of prostate cancer Update and Controversies in Uro-oncology, Lac Carling, P.Q. October, 1997
161. La biotechnologie, votre sante, votre avenir, votre investissement Conference Theatre Le Capitole, Quebec September, 1997
162. 24th International Congress of the Societe Internationale d Urologie Montreal Reporter of the Plenary session on Invasive Bladder Cancer September, 1997
163. Defining Curability in Prostate Cancer International Symposium Vienna, Austria June, 1997
164. Diagnostic and Prognostic Markers in Bladder Cancer President of the organizing committee for the International Workshop April, 1997
165. Journee d Urologie du Groupe Necker, Paris on Prostate cancer Journee d Urologie du Groupe Necker, Paris on Prostate cancer March, 1997
166. The treatment of prostate cancer: How is failure defined and how cant it be minimized? Prostate cancer: the 1997 Conference March, 1997
167. 17th Jackson Hole Urologic Conference, Jackson Hole, Wyoming New Emerging Tests for the Management of Bladder Cancer January, 1997
168. Principles of differentiation Emerging Concepts in Late Stage Prostate Cancer - Teaching Program November, 1996
169. Critique speaker on adjuvant and neoadjuvant treatments A European-American Encounter, Munich, Germany November, 1996
170. A prostate cancer case - Stage B1 with increasing PSA Urology Program - Manoir des Sables, Orford September, 1996
171. Screening for prostate cancer and optimal management of localized disease University of Winnipeg April, 1996
172. Criteria for conducting clinical trials in advanced prostate cancer Prostate cancer: the 1996 Conference March, 1996
173. Role of tumor markers in the treatment of bladder cancer Nijmegen University, Netherlands January, 1996
174. New biological markers in bladder cancer An International Symposium, Université Libre de Bruxelles, Belgium January, 1996
175. Urologic Oncology Update Scientific program Luxor, Egypt October, 1995
176. Prognostic factors in superficial transitional cell carcinoma - Panel discussions Bladder Cancer Conference - Halifax September, 1995
177. Biological and clinical advances in the management of bladder cancer 5th Annual meeting, Canadian Society of University Urology Residents, Ottawa June, 1995
178. Prognostic factors: past, present and future 2nd International Symposium on Bladder Cancer - Superficial Bladder Cancer: The state of the art, Padova, Italy May, 1995
179. The management of invasive bladder cancer: impact of bladder reconstruction and chemotherapy Northeastern Ontario Urology Update, Timmins, Ontario May, 1995
180. Advances in the management of bladder cancer: implication of tumor markers. University of British Columbia April, 1995
181. What are the potential benefits to neoadjuvant therapy? Prostate Cancer Conference -The 1995 Conference, March, 1995
182. Lecturer on prostate and bladder cancers Fourth Continual Medical Education Retreat (Jewish General Urology Hospital), Stowe, Vermont March, 1995
183. Bladder tumor markers and their prognostic significance University of Alberta January, 1995
184. Diagnosis of bladder cancer and monitoring New Brunswick Urological Group November, 1994
185. Visiting Professor Harvard Medical School November, 1994
186. Antigenic analysis of bladder cancer and the potential for antibody directed therapy for bladder carcinoma Society for Basic Urologic Research Fall Symposium, Stanford, California October, 1994
187. Significant effect of short-term hormonotherapy on prostatic intra-epithelial neoplasia at radical prostatectomy. Societe Internationale d Urologie, Sydney, Australie September, 1994
188. Modern Advances in Bladder Cancer Research 2nd Annual James R. Geyer Symposium June, 1994
189. Prognostic value of molecular anomalies in bladder cancer Workshop on the application of molecular biology to cancer control; new avenues for epidemiologic research. Montreal May, 1994
190. Urology Urology Medical Advisory Council Meeting April, 1994
191. Clinical uses of molecular information: when will it be here? Society of Urologic Oncology, San Francisco, California April, 1994
192. American Association of Genitourinary Surgeons, Boca Raton, Florida American Association of Genitourinary Surgeons, Boca Raton, Florida April, 1994
193. Screening for Prostate Cancer, Quebec Chairman of the Canadian Workshop March, 1994
194. Issues & Controversies Prostate Cancer 1994 Conference, Whistler, British Columbia March, 1994
195. Neoadjuvant hormonal therapy and radical prostatectomy Fourth International prostate Cancer Update, Vail, Colorado January, 1994
196. Progression markers in bladder cancer and their clinical relevance. Second annual Genitourinary Oncology Conference - M.D. Anderson Cancer Center, University of Texas. January, 1994
197. Staging of invasive bladder cancer: is there any improvement? Third European Urological Winter Forum, Davos, Switzerland January, 1994
198. Royal College of Physicians and Surgeons of Canada Canadian Urological Association January, 1994
199. Recent advances in the management of prostate cancer University of London, Ontario December, 1993
200. Bladder reconstruction Management of Kidney Cancer November, 1993
201. Abbott Prostate Advisory Board Meeting, Toronto Abbott Prostate Advisory Board Meeting, Toronto October, 1993
202. New molecular markers of bladder cancer and their clinical implications Ottawa Civic Hospital, Ottawa October, 1993
203. New Ideas, approaches and techniques University of Toronto October, 1993
204. Patient information in the management of prostatic cancer Berlex Advisory Board Meeting - Montebello September, 1993
205. New considerations in prostate cancer. Queens University, Kingston, Ontario. July, 1993
206. Bladder reconstruction and adjuvant chemotherapy in invasive bladder cancer Symposium sur le cancer de la vessie, Québec June, 1993
207. Merck Frosst Urology Medical Advisory Council Meeting, Key Largo, Florida Meeting on superficial bladder cancer April, 1993
208. Advances in management of invasive bladder cancer and continent urinary diversion. Baylor University Medical Center, Dallas. April, 1993
209. Committee aetiology of bladder cancer and tumor markers. Fourth International Concensus Meeting on Bladder Cancer, Antwerp, Belgium March, 1993
210. Issues & Controversies in Prostate Cancer Quebec Guest speaker: March, 1993
211. sur la recherche sur le cancer l'intention des redacteurs scientifiques organise par la Social Canadienne du Cancer Universite Laval, 3rd symposium January, 1993
212. Royal College of Physicians and Surgeons - Urology Nucleus Committee, Royal College of Physicians and Surgeons - Urology Nucleus Committee, January, 1993
213. Impact des innovations chirurgicales et des marqueurs biologiques dans le traitement du cancer de la vessie. Journee dOncologie, Montreal - Dr Jacques Jolivet October, 1992
214. Dilemmas in management of prostate and bladder cancers Guest speaker: International Symposium October, 1992
215. Ploidy and bladder cancer NIH Concensus conference October, 1992
216. Guest speaker Spanish Health Organization Workshop on Bladder Cancer September, 1992
217. Tumor-associated antigens NIH Workshop July, 1992
218. Prognostic factors in prostatic cancer Third International Symposium June, 1992
219. Guest speaker Merck Frosst Medical Advisory Council-Scientific Programme April, 1992
220. Guest speaker Baylor University Medical Center, Dallas Texas April, 1992
221. Urology Research Society, Hilton Head, South Carolina Urology Research Society, Hilton Head, South Carolina April, 1992
222. Treatment of early-stage prostate cancer NIH Strategy Meeting March, 1992
223. Molecular and immunologic approaches in the management of bladder cancer Visiting professor - Division of Urology, University of British Columbia March, 1992
224. Visiting professor Division of Urology, University of Toronto March, 1992
225. Issues and controversies in prostate cancer First Canadian Conference March, 1992
226. Molecular and immunologic approaches in the management of bladder cancer University of British Columbia, Division of Urology March, 1992
227. Mise a jour sur le cancer de la prostate Urologues de Montreal-Nord January, 1992
228. Prognostic indicators in prostate cancer Societe Internationale d Urologie, Seville, Espagne - Satellite Symposium on Diagnosis and Management of prostatic disease. November, 1991
229. Guest speaker Department of Immunology, University of Barcelone October, 1991
230. Cancer de la vessie: un point de convergence biologique et clinique 63e Congres-Exposition international de l Association des Medecins de langue francaise October, 1991
231. study design for evaluation of diagnostic and prognostic markers for cancer, Washington. Organizing Committee Workshop NIH/USA September, 1991
232. Carcinoma of the prostate, Royal College of Surgeons and Physicians, Quebec. Canadian Association of Radiation Oncologists September, 1991
233. Special Symposium on invasive bladder cancer: sujet: Molecular markers of prognosis in invasive bladder cancer American Urological Association Annual Meeting. June, 1991
234. Markers of prognosis in superficial bladder cancer International Society of Urologic Oncology, Toronto June, 1991
235. Institut du Cancer de Montreal Institut du Cancer de Montreal May, 1991
236. Workshop on Bladder reconstruction, Sherbrooke Workshop on Bladder reconstruction, Sherbrooke May, 1991
237. Current issues in the management of prostate cancer Conference in Toronto (Mississauga) for urologists- Berlex Canada Inc. April, 1991
238. Current issues in the management of prostate cancer Conference in Montreal for urologists - Berlex Canada Inc. April, 1991
239. Current issues in the management of prostate cancer Conference in Toronto (Scarborough) for urologists- Berlex Canada Inc. April, 1991
240. Guest speaker: Bladder cancer: a point of convergence for basic research and clinical applications McGill University- 1st Urology Research Day April, 1991
241. Urologues de l Ouest Meeting of Urologues de l Ouest Societe Française d Urologie April, 1991
242. Controversies in the management of transitional cell carcinoma of the bladder Educational course, Americian Society of Clinical Oncology (ASCO) Meeting, Houston, Texas April, 1991
243. 5th Annual Genito-urinary Cancer Update, Denver Colorado Tumor markers March, 1991
244. The use of markers in bladder cancer and discussions of the bladder cancer network. 1991 CAS Users meeting and educational seminar, Scottsdale, Arizona January, 1991
245. New Trends in Diagnosis and Management of Prostatic Diseases, Naples, Florida New Trends in Diagnosis and Management of Prostatic Diseases, Naples, Florida January, 1991
246. Visiting professor Queens University Urology Department January, 1991
247. Clinical and biological implications of monoclonal antibodies to bladder tumor associated antigen Willet F. Whitmore Symposium on Advances in Urologic Oncology (2 conferences) December, 1990
248. Guest speaker: Oncology Rounds New York Medical College, Valhalla, New York November, 1990
249. Guest speaker New York Medical College, Valhalla, New York November, 1990
250. XVe Rencontre annuelle de l Association des Urologues du Quebec, Montreal Presentation du Groupe Canadien d Uro-Oncologie (CUOG) November, 1990
251. International Conference on Molecular Genetics of Bladder Cancer invitation from the NIH), Prouts Neck, Maine October, 1990
252. Symposium sur l utilisation de la flux-cytometrie en clinique. Flow cytometry in bladder and prostate cancer Hospital Ste-Justine October, 1990
253. Symposium sur les maladies de la prostate - Berlin Symposium sur les maladies de la prostate - Berlin September, 1990
254. Urological Research Society 9th Annual meeting - Hannover, Germany September, 1990
255. Workshop Overview Randomized Trials Ml Prostate Cancer with Combination Treatment - Paris, France Workshop Overview Randomized Trials Ml Prostate Cancer with Combination Treatment - Paris, France June, 1990
256. Oncology Research Canadian Urological Association - Vancouver June, 1990
257. Recent Advances in Urological Cancer Diagnosis and Treatment 2nd International Symposium June, 1990
258. Adenocarcinome de la prostate - Investigation et traitement Journee d Education medicale continue, Centre hospitalier St-Joseph Trois-Rivieres May, 1990
259. Visiting professor Hamilton Regional Cancer Center and Department of Urology April, 1990
260. Symposium on Contemporary trends in bladder cancer detection and treatment, New Orleans Symposium on Contemporary trends in bladder cancer detection and treatment, New Orleans April, 1990
261. Moderator- poster session - Bladder Tumors: Superficial II American Urological Association - New Orleans, LA April, 1990
262. Bladder cancer: prognostic indicators Northeastern Section Seminar of the American Urological Association (AUA), Montreal April, 1990
263. Conference Centre hospitalier universitaire de Sherbrooke. Reunion d uro-oncologie March, 1990
264. Presentation of the Canadian Uro-Oncology Group (CUOG XVe Annual Meeting of the Quebec Association of Urologists, Montreal January, 1990
265. Visiting professor Department of Urology, Faculty of Medicine, University de Grenoble, France January, 1990
266. Guest speaker Centre d Energie Nucleaire de Grenoble, France January, 1990
267. Guest speaker at the Dean's Conference Faculty of Medicine, Université de Grenoble, France January, 1990
268. Nouvelles technologies en urologie Guest speaker - The Quebec Surgical Society, Quebec November, 1989
269. Prognostic indicators in bladder cancer Guest speaker -Urologic Oncology Today & Tomorrow, Toronto October, 1989
270. Role of total androgen blockade in prostate cancer - quality control and clinical trials strategies American Cancer Society, International Workshop by invitation September, 1989
271. Molecular markers of superficial and aggressive human bladder cancers American Association for Cancer Research (AACR) May, 1989
272. Predictors of response and progression in bladder cancer Frontiers in Uro-Oncology, London, Ontario April, 1989
273. Conference on prostatic cancer Jewish General Hospital, Montreal. April, 1989
274. Role of surgery and new concepts in the management of localized carcinoma of the prostate French Society of Oncology, Martinique March, 1989
275. Visiting professor Departments of Pathology and Urology Rush Presbyterian Medical College January, 1989
276. Visiting professor Department of Surgery and Cross Cancer Institute, Edmonton, Alberta, Canada December, 1988
277. Mini-symposium on Advanced Prostate Cancer, Hamilton, Bermuda Carcinoma of the prostate: epidemiology, biology and prognostic factors Mini-symposium on Advanced Prostate Cancer, Hamilton, Bermuda Carcinoma of the prostate: epidemiology, biology and prognostic factors November, 1988
278. Presentation on Laval University Life Sciences Projects Technology Transfer Conferences Inc., Montreal, Canada October, 1988
279. Visiting professor Department of Urology at the University of Oklahoma, USA October, 1988
280. Role of radical prostatectomy and new concepts International Symposium on Diagnosis and Treatment of Localized Carcinoma of the Prostate, Quebec October, 1988
281. Oncology research seminar, by invitation. American Urological Association, Houston, Texas July, 1988
282. From molecular studies to reconstructive surgery: the possible implications for clinical management of human bladder cancer Canadian Academy of Urological Surgeons, Halifax June, 1988
283. Westchester Surgical Society, Quebec Westchester Surgical Society, Quebec May, 1988
284. Prognosis of human cancers as determined by flow cytometry with monoclonal antibodies. Southern Society of Clinical Surgeons, Quebec meeting April, 1988
285. Urology Research Seminar Memorial Sloan Kettering Cancer Center, New York January, 1988
286. A Canadian multicenter randomized double-blind study of castration with placebo or Anandron in metastatic cancer. International Symposium on GnRH analogues in cancer and human reproduction, Geneva, Switzerland. January, 1988
287. Biological behaviour and immunological characterisation of bladder cancer cells Urology Klinik, Bern University Hospital, Switzerland. January, 1988
288. Visiting Professor Department of Urology, Dalhousie University, Halifax, Nova Scotia. October, 1987
289. Symposium on new developments in Molecular Oncology Canadian Society of Laboratory Medicine June, 1987
290. Visiting Scientist and guest speaker Cambridge Research Laboratories, Cambridge, Mass March, 1987
291. Clinical implications of monoclonal antibodies to bladder cancer. 38th Annual Meeting, Northeastern section of American Urological Association September, 1986
292. Flowcytometry study of bladder cancer with monoclonal antibodies Department of Urology, Massachusetts General Hospital, Boston May, 1986
293. Visiting professor Department of Urology, McGill University, Montreal December, 1985
294. Mise a jour sur les anticorps monoclonaux. l0th Annual Meeting of Quebec Association of Urologists, Quebec November, 1985
295. Multiparameter flowcytometry in bladder cancer. University of Toronto October, 1985
296. The biology of bladder cancer and the implications of monoclonal antibodies. University of Toronto, Urology Department March, 1985
297. Cancer immunology and monoclonal antibodies Montreal University, Urology Department December, 1984
298. Mise a jour sur les tumeurs testiculaires. 9th Annual Meeting of Quebec Association of Urologists, Montreal November, 1984
299. Monoclonal antibodies to human urinary bladder tumors; characterization and some applications 1984 Urologic Tumor Symposium, Memorial Sloan-Kettering Cancer Center, New York November, 1984
300. Principles and applications of monoclonal antibodies Association des Technologistes Medicaux du Quebec June, 1984
301. Monoclonal Antibodies Workshop. Canadian Federation of Biological Societies, University of Saskatchewan, Saskatoon June, 1984
302. Monoclonal antibodies to human bladder cancer McGill Cancer Center, Montreal April, 1984
303. Germ cell tumors of the testis Memorial Sloan-Kettering Cancer Center, New York May, 1983
304. Monoclonal antibodies against human cancer Memorial Sloan-Kettering Cancer Center, New York April, 1983



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Central Room A | Session topic: Biomarkers Australian-Canadian Prostate Cancer Research Alliance Symposium August, 2010
Biomarkers | Central Room A 2010 Australian-Canadian Prostate Cancer Research Alliance (AC-PCRA) Symposium August, 2010

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.